Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases
- PMID: 34785569
- PMCID: PMC8596057
- DOI: 10.1136/lupus-2021-000561
Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases
Abstract
Objective: The risk of developing diffuse large B-cell lymphoma (DLBCL) is increased in many rheumatic diseases (RDs). It is possible that RD-associated DLBCL is a distinct subset within the category of 'DLBCL', exhibiting characteristic biological features and clinical behaviour. However, information on RD-associated DLBCL is limited.
Methods: We searched the V.A. Nasonova Research Institute of Rheumatology (Russia) database from 1996 to 2021 for patients with RDs and coexisting DLBCL. Prognostic factors including the International Prognostic Index (IPI), bulk disease and c-MYC/8q24 gene rearrangements were analysed. Furthermore, we stratified DLBCLs as germinal centre B-cell (GCB) subtype and non-GCB subtype based on Hans' immunohistochemical algorithm and also examined Epstein-Barr virus (EBV) status.
Results: Twenty-seven patients with RD-associated DLBCL were identified. Twenty patients had primary Sjogren's syndrome, three had systemic lupus erythematosus, two had rheumatoid arthritis and two had systemic sclerosis. Secondary Sjogren's syndrome was found in four patients. The median age at the time of diagnosis of DLBCL was 59 years with a female predominance (26:1). Based on IPI, 16 patients were assigned to the intermediate-high and high-risk groups. Bulk disease was detected in 29% of patients. Of the 20 examined cases, 4 (20%) were classified as the GCB subtype and 16 (80%) were classified as the non-GCB subtype. EBV was detected in 2 of the 21 tested cases (10%), and the c-MYC/8q24 gene rearrangement was not found in any of the 19 examined cases. After the lymphoma diagnosis, the median overall survival (OS) was 10 months (range: 0-238 months).
Conclusions: Except for the more common non-GCB subtype, we did not identify any other prognostic factor that could influence the prognosis of patients with RD-associated DLBCL. We believe that short OS in our patients was predominantly associated with decreased tolerance to lymphoma treatment.
Keywords: B lymphocytes; autoimmune diseases; quality of life.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Characteristics of diffuse large B-cell lymphoma in patients with primary Sjögren's syndrome.Int J Rheum Dis. 2020 Apr;23(4):540-548. doi: 10.1111/1756-185X.13800. Epub 2020 Feb 25. Int J Rheum Dis. 2020. PMID: 32100426 Free PMC article.
-
Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.Int J Med Sci. 2019 Apr 20;16(4):556-566. doi: 10.7150/ijms.27610. eCollection 2019. Int J Med Sci. 2019. PMID: 31171907 Free PMC article.
-
[Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].Zhonghua Bing Li Xue Za Zhi. 2011 Apr;40(4):235-9. Zhonghua Bing Li Xue Za Zhi. 2011. PMID: 21615996 Chinese.
-
Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature.Rheumatol Int. 2020 Mar;40(3):499-506. doi: 10.1007/s00296-019-04470-x. Epub 2019 Nov 9. Rheumatol Int. 2020. PMID: 31707561 Review.
-
Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature.J Clin Exp Hematop. 2012;52(3):211-8. doi: 10.3960/jslrt.52.211. J Clin Exp Hematop. 2012. PMID: 23269082 Review.
Cited by
-
Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.J Immunol Res. 2022 Sep 28;2022:5633096. doi: 10.1155/2022/5633096. eCollection 2022. J Immunol Res. 2022. PMID: 36213322 Free PMC article.
-
Epstein-Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma.Life (Basel). 2023 Feb 14;13(2):521. doi: 10.3390/life13020521. Life (Basel). 2023. PMID: 36836878 Free PMC article. Review.
-
Clinical Characteristics of Distinct Subgroups of Patients with Primary Sjögren's Syndrome Classified by Serological Profiles: A Comparison Study.J Pers Med. 2024 Sep 12;14(9):967. doi: 10.3390/jpm14090967. J Pers Med. 2024. PMID: 39338221 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous